Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination.

Pol JG, Bridle BW, Lichty BD.

Methods Mol Biol. 2020;2058:191-211. doi: 10.1007/978-1-4939-9794-7_12.


Trial watch: dietary interventions for cancer therapy.

Lévesque S, Pol JG, Ferrere G, Galluzzi L, Zitvogel L, Kroemer G.

Oncoimmunology. 2019 Apr 3;8(7):1591878. doi: 10.1080/2162402X.2019.1591878. eCollection 2019. Review.


Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.

Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA.

Oncoimmunology. 2018 Sep 19;8(1):e1512329. doi: 10.1080/2162402X.2018.1512329. eCollection 2019.


Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018. Review.


Development and applications of oncolytic Maraba virus vaccines.

Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD.

Oncolytic Virother. 2018 Nov 26;7:117-128. doi: 10.2147/OV.S154494. eCollection 2018. Review.


Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models.

Humeau J, Lévesque S, Kroemer G, Pol JG.

Methods Mol Biol. 2019;1884:297-315. doi: 10.1007/978-1-4939-8885-3_21.


Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies.

Gujar S, Pol JG, Kroemer G.

Oncoimmunology. 2018 Mar 13;7(8):e1442169. doi: 10.1080/2162402X.2018.1442169. eCollection 2018.


Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.

Gujar S, Pol JG, Kim Y, Lee PW, Kroemer G.

Trends Immunol. 2018 Mar;39(3):209-221. doi: 10.1016/ Epub 2017 Dec 20. Review.


Trial watch: DNA-based vaccines for oncological indications.

Pierini S, Perales-Linares R, Uribe-Herranz M, Pol JG, Zitvogel L, Kroemer G, Facciabene A, Galluzzi L.

Oncoimmunology. 2017 Nov 20;6(12):e1398878. doi: 10.1080/2162402X.2017.1398878. eCollection 2017. Review.


S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3.

Wang F, Alain T, Szretter KJ, Stephenson K, Pol JG, Atherton MJ, Hoang HD, Fonseca BD, Zakaria C, Chen L, Rangwala Z, Hesch A, Chan ESY, Tuinman C, Suthar MS, Jiang Z, Ashkar AA, Thomas G, Kozma SC, Gale M Jr, Fitzgerald KA, Diamond MS, Mossman K, Sonenberg N, Wan Y, Lichty BD.

Nat Immunol. 2016 May;17(5):514-522. doi: 10.1038/ni.3433. Epub 2016 Apr 4.


Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-α-stimulated signaling pathways and limits the extent of liver inflammation.

Pol JG, Lekbaby B, Redelsperger F, Klamer S, Mandouri Y, Ahodantin J, Bieche I, Lefevre M, Souque P, Charneau P, Gadessaud N, Kremsdorf D, Soussan P.

FASEB J. 2015 May;29(5):1879-89. doi: 10.1096/fj.14-258715. Epub 2015 Jan 28.


Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.

Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL.

Cancer Immunol Res. 2013 Nov;1(5):309-19. doi: 10.1158/2326-6066.CIR-13-0059-T. Epub 2013 Aug 19.


Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL.

Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9.


Maraba virus as a potent oncolytic vaccine vector.

Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, Wan Y, Lichty BD.

Mol Ther. 2014 Feb;22(2):420-429. doi: 10.1038/mt.2013.249. Epub 2013 Oct 25.


Panorama from the oncolytic virotherapy summit.

Pol JG, Marguerie M, Arulanandam R, Bell JC, Lichty BD.

Mol Ther. 2013 Oct;21(10):1814-8. doi: 10.1038/mt.2013.207. No abstract available.


Jejunal atresia related to the use of methylene blue in genetic amniocentesis in twins.

van der Pol JG, Wolf H, Boer K, Treffers PE, Leschot NJ, Hey HA, Vos A.

Br J Obstet Gynaecol. 1992 Feb;99(2):141-3.


Genetic amniocentesis in twin pregnancies: results of a multicenter study of 529 cases.

Pruggmayer MR, Jahoda MG, Van der Pol JG, Baumann P, Holzgreve W, Karkut G, Lettau R, Eiben B, Osmers R, Gola HW, Duda V, Polak P, Körner H, Schulte-Valentin M, Schütte H.

Ultrasound Obstet Gynecol. 1992 Jan 1;2(1):6-10.


Clinical bedrest in twin pregnancies.

van der Pol JG, Bleker OP, Treffers PE.

Eur J Obstet Gynecol Reprod Biol. 1982 Nov;14(2):75-80.


Supplemental Content

Support Center